RE:RE:RE:RE:RE:RE:RE:The potential oncology collaboration..Jounce is interesting. As of their last quarter they had US$157M in cash and marketable securities; 52M shares outstanding. So, about $/share 3 in cash, PLUS they just received an additional US$15M from Gilead, and the stock is trading around US$2/share. The problem is the market knows all of that money will be used up in drug development and clinical trials. In fact, the US$15M would be used up in about 3 months (give or take). They need further success with their 2 other clinincal trials (or further milestone payments from Gilead) in order to survive and thrive.
THTX needs some positive clinical responses with TH1902, hopefully before Christmas. Would a complete response be asking too much? That would be material....Yes/No?